RBC Capital raised the firm’s price target on Cytokinetics (CYTK) to $95 from $87 and keeps an Outperform rating on the shares. The FDA approved the company’s Myqorzo ahead of their highly anticipated December 26th PDUFA, as the label and REMS come in better than the firm’s base-case, with flexible titration, infrequent echo monitoring, wide windows, and minimal drug-drug interaction, which should materially lower barriers to prescribing vs. Camzyos, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating
- Cytokinetics price target raised to $99 from $95 at Goldman Sachs
- Cytokinetics price target raised to $88 from $78 at Citizens
- Cytokinetics price target raised to $136 from $120 at H.C. Wainwright
- Cytokinetics price target raised to $87 from $82 at Barclays